741 related articles for article (PubMed ID: 32345485)
41. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
[TBL] [Abstract][Full Text] [Related]
42. COVID-19 convalescent plasma: phase 2.
Knudson CM; Jackson JB
Transfusion; 2020 Jun; 60(6):1332-1333. PubMed ID: 32374890
[TBL] [Abstract][Full Text] [Related]
43. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
[TBL] [Abstract][Full Text] [Related]
44. Immunotherapeutic approaches to curtail COVID-19.
Owji H; Negahdaripour M; Hajighahramani N
Int Immunopharmacol; 2020 Nov; 88():106924. PubMed ID: 32877828
[TBL] [Abstract][Full Text] [Related]
45. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.
Zhou G; Zhao Q
Int J Biol Sci; 2020; 16(10):1718-1723. PubMed ID: 32226289
[TBL] [Abstract][Full Text] [Related]
46. Convalescent Plasma: Promise for COVID-19 Pandemic.
Sheikh S; Baig MA
J Coll Physicians Surg Pak; 2020 Jun; 30(6):88. PubMed ID: 32723468
[No Abstract] [Full Text] [Related]
47. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq.
Rasheed AM; Fatak DF; Hashim HA; Maulood MF; Kabah KK; Almusawi YA; Abdulamir AS
Infez Med; 2020 Sep; 28(3):357-366. PubMed ID: 32920571
[TBL] [Abstract][Full Text] [Related]
48. Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays.
DomBourian MG; Annen K; Huey L; Andersen G; Merkel PA; Jung S; Dominguez SR; Knight V
J Immunol Methods; 2020 Nov; 486():112837. PubMed ID: 32828791
[TBL] [Abstract][Full Text] [Related]
49. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019.
Zeng QL; Yu ZJ; Gou JJ; Li GM; Ma SH; Zhang GF; Xu JH; Lin WB; Cui GL; Zhang MM; Li C; Wang ZS; Zhang ZH; Liu ZS
J Infect Dis; 2020 Jun; 222(1):38-43. PubMed ID: 32348485
[TBL] [Abstract][Full Text] [Related]
50. Convalescent Plasma and COVID-19.
Malani AN; Sherbeck JP; Malani PN
JAMA; 2020 Aug; 324(5):524. PubMed ID: 32530454
[No Abstract] [Full Text] [Related]
51. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.
Accorsi P; Berti P; de Angelis V; De Silvestro G; Mascaretti L; Ostuni A;
Blood Transfus; 2020 May; 18(3):163-166. PubMed ID: 32453687
[TBL] [Abstract][Full Text] [Related]
52. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
53. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
[TBL] [Abstract][Full Text] [Related]
54. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.
de Alwis R; Chen S; Gan ES; Ooi EE
EBioMedicine; 2020 May; 55():102768. PubMed ID: 32344202
[TBL] [Abstract][Full Text] [Related]
55. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design.
Barone P; DeSimone RA
Transfusion; 2020 Jun; 60(6):1123-1127. PubMed ID: 32374891
[TBL] [Abstract][Full Text] [Related]
56. Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres.
Mehew J; Johnson R; Roberts D; Griffiths A; Harvala H
Transfus Med; 2022 Aug; 32(4):327-337. PubMed ID: 35434868
[TBL] [Abstract][Full Text] [Related]
57. Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles.
Im JH; Nahm CH; Baek JH; Kwon HY; Lee JS
J Korean Med Sci; 2020 Jul; 35(26):e239. PubMed ID: 32627442
[TBL] [Abstract][Full Text] [Related]
58. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.
Shih HI; Wu CJ; Tu YF; Chi CY
Biomed J; 2020 Aug; 43(4):341-354. PubMed ID: 32532623
[TBL] [Abstract][Full Text] [Related]
59. Audio Interview: Capitalizing on Immune Responses to Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 May; 382(21):e93. PubMed ID: 32433859
[No Abstract] [Full Text] [Related]
60. Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment.
Sheervalilou R; Shirvaliloo M; Sargazi S; Bahari S; Saravani R; Shahraki J; Shirvalilou S; Shahraki O; Nazarlou Z; Shams Z; Ghaznavi H
Blood Purif; 2022; 51(1):1-14. PubMed ID: 33789273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
